TriSalus Life Sciences, Inc. filings document operating results, governance actions and capital-structure matters for an oncology-focused medical technology company. Form 8-K reports cover financial results, business updates, guidance, material events, leadership changes, board composition and Regulation FD disclosures tied to TriNav, PEDD and related oncology development activity.
Proxy materials describe shareholder voting matters, director elections, board committees, executive compensation and equity awards. The filing record also includes capital-structure disclosures for common stock and warrants, material-agreement categories, clinical or regulatory disclosure topics and risk-related information associated with commercializing PEDD infusion systems and developing investigational therapies for solid tumors.
TriSalus Life Sciences insider award summary: Chief Financial Officer David Patience received equity awards on 08/14/2025 consisting of 200,000 restricted stock units (RSUs) payable in common stock and an employee stock option to purchase 290,000 shares at an exercise price of $3.88 per share. Following these grants, the reporting person beneficially owns 200,000 common shares and 290,000 option shares directly. The RSUs vest in four equal annual installments beginning July 1, 2026, subject to continued service. The option vests 25% on the one-year anniversary of the July 1, 2026 vesting commencement date, with the remainder vesting monthly thereafter until fully vested, and expires on 08/13/2035.
TriSalus Life Sciences received a Schedule 13G reporting that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, each may be deemed the beneficial owner of 2,000,000 shares of TriSalus common stock, representing 5.29% of the class as of June 30, 2025. The filing states the shares are held by funds and separately managed accounts under Nantahala's control, and the reported position reflects shared voting and dispositive power only, with no sole voting or sole dispositive authority. The Reporting Persons certify the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
TriSalus Life Sciences reported accelerating product revenue and improved liquidity but continues to record operating losses and faces substantial doubt about its ability to continue as a going concern. Revenue for Q2 2025 rose to $11.213 million from $7.364 million a year earlier, producing gross profit of $9.411 million for the quarter and $17.083 million for the six months ended June 30, 2025, compared with $11.938 million a year earlier. Cash and cash equivalents increased to $26.8 million at June 30, 2025 from $8.5 million at year-end 2024, driven primarily by a $22.0 million private placement and draws under the OrbiMed Credit Agreement.
The company reported a six-month net loss available to common stockholders of $18.663 million and an accumulated deficit of $298.2 million. Total assets were $41.3 million versus total liabilities of $60.7 million, producing a stockholders' deficit of $19.4 million. Management disclosed substantial doubt about near-term liquidity and expects to require additional capital through collaborations, equity or debt to fund operations.
TriSalus Life Sciences, Inc. filed a current report to note that on August 12, 2025 it issued a press release providing a business update and announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is treated as furnished, not filed, under securities laws, which limits its use in certain types of investor lawsuits and in other company filings unless specifically incorporated by reference.